摘要
评价血清中AMS(淀粉酶)、Lipase(脂肪酶)、CA19-9、CA125和CEA联合检测在胰腺疾病中的临床应用价值。对我院2009年6月至12月,经病理诊断为胰腺疾病的216例住院患者的AMS、Lipase、CA19-9、CA125和CEA检测结果采用SPSS软件作回顾性分析。结果显示,胰腺癌(PC)组与慢性胰腺炎(CP)组比较,CA19-9、CA125、CEA水平明显升高(P<0.01),AMS则明显降低(P<0.01),Lipase在两组间没有显著性差异;与急性胰腺炎(AP)组比较,CA19-9、CEA水平显著升高(P<0.01),而Lipase、AMS明显降低(P<0.01),CA125在两组间没有显著性差异。以上结果表明,CA19-9、CEA、CA125和AMS的联合检测可以辅助临床胰腺疾病的鉴别诊断。
To investigate the clinical value of combined measurement of serum lipase,AMS,CA19-9,CA125 and CEA in the diagnosis of pancreatitis and pancreatic cancer,the serum levels of these five biomarkers in 216 patients with pancreatitis and pancreatic cancer（PC） were measured and the results were analyzed retrospectively.The results showed that the serum levels of CA199,CA125 and CEA in patients with pancreatic cancer were significantly higher than that of patients with the chronic pancreatitis（CP）（P0.01）,while the serum AMS was lower than that of in CP group（P0.01）.There was no significant difference for serum lipase between two groups.Compared with acute pancreatitis（AP）group,the serum CA199 and CEA were higher significantly in patients with pancreatic cancer（P0.01）,while the serum lipase and AMS were significantly low（P0.01）.There was no significant difference for serum CA125 between two groups.The results indicate that the combined detection of CA199,CA125,CEA and AMS could be helpful in the differential diagnosis of patients with pancreatic cancer from pancreatitis diseases.
出处
《标记免疫分析与临床》
CAS
2010年第4期220-222,共3页
Labeled Immunoassays and Clinical Medicine
基金
国家科技部重大专项(2008AA022602)
关键词
慢性胰腺炎
急性胰腺炎
胰腺癌
生物指标
Chronic pancreatitis
Acute pancreatitis
Pancreatic cancer
Biomarker
